These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34078222)

  • 1. A case report of infantile parkinsonism-dystonia-2 caused by homozygous mutation in the
    Zhai H; Zheng Y; He Y; Zhang Y; Guo Z; Cui W; Sun L
    Int J Neurosci; 2023 May; 133(5):574-577. PubMed ID: 34078222
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals.
    Saida K; Maroofian R; Sengoku T; Mitani T; Pagnamenta AT; Marafi D; Zaki MS; O'Brien TJ; Karimiani EG; Kaiyrzhanov R; Takizawa M; Ohori S; Leong HY; Akay G; Galehdari H; Zamani M; Romy R; Carroll CJ; Toosi MB; Ashrafzadeh F; Imannezhad S; Malek H; Ahangari N; Tomoum H; Gowda VK; Srinivasan VM; Murphy D; Dominik N; Elbendary HM; Rafat K; Yilmaz S; Kanmaz S; Serin M; Krishnakumar D; Gardham A; Maw A; Rao TS; Alsubhi S; Srour M; Buhas D; Jewett T; Goldberg RE; Shamseldin H; Frengen E; Misceo D; Strømme P; Magliocco Ceroni JR; Kim CA; Yesil G; Sengenc E; Guler S; Hull M; Parnes M; Aktas D; Anlar B; Bayram Y; Pehlivan D; Posey JE; Alavi S; Madani Manshadi SA; Alzaidan H; Al-Owain M; Alabdi L; Abdulwahab F; Sekiguchi F; Hamanaka K; Fujita A; Uchiyama Y; Mizuguchi T; Miyatake S; Miyake N; Elshafie RM; Salayev K; Guliyeva U; Alkuraya FS; Gleeson JG; Monaghan KG; Langley KG; Yang H; Motavaf M; Safari S; Alipour M; Ogata K; Brown AEX; Lupski JR; Houlden H; Matsumoto N
    Genet Med; 2023 Jan; 25(1):90-102. PubMed ID: 36318270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain dopamine-serotonin vesicular transport disease and its treatment.
    Rilstone JJ; Alkhater RA; Minassian BA
    N Engl J Med; 2013 Feb; 368(6):543-50. PubMed ID: 23363473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exome sequencing results in identification and treatment of brain dopamine-serotonin vesicular transport disease.
    Rath M; Korenke GC; Najm J; Hoffmann GF; Hagendorff A; Strom TM; Felbor U
    J Neurol Sci; 2017 Aug; 379():296-297. PubMed ID: 28716265
    [No Abstract]   [Full Text] [Related]  

  • 5. Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder.
    Jacobsen JC; Wilson C; Cunningham V; Glamuzina E; Prosser DO; Love DR; Burgess T; Taylor J; Swan B; Hill R; Robertson SP; Snell RG; Lehnert K
    J Inherit Metab Dis; 2016 Mar; 39(2):305-8. PubMed ID: 26497564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel SLC18A2 Variant in Infantile Dystonia-Parkinsonism Type 2.
    Kaasalainen S; Arikka H; Martikainen MH; Kaasinen V
    Case Rep Neurol Med; 2024; 2024():4767647. PubMed ID: 38716424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is new for monoamine neurotransmitter disorders?
    Marecos C; Ng J; Kurian MA
    J Inherit Metab Dis; 2014 Jul; 37(4):619-26. PubMed ID: 24696406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood.
    Ng J; Zhen J; Meyer E; Erreger K; Li Y; Kakar N; Ahmad J; Thiele H; Kubisch C; Rider NL; Morton DH; Strauss KA; Puffenberger EG; D'Agnano D; Anikster Y; Carducci C; Hyland K; Rotstein M; Leuzzi V; Borck G; Reith ME; Kurian MA
    Brain; 2014 Apr; 137(Pt 4):1107-19. PubMed ID: 24613933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
    Lohr KM; Bernstein AI; Stout KA; Dunn AR; Lazo CR; Alter SP; Wang M; Li Y; Fan X; Hess EJ; Yi H; Vecchio LM; Goldstein DS; Guillot TS; Salahpour A; Miller GW
    Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9977-82. PubMed ID: 24979780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling brain dopamine-serotonin vesicular transport disease in
    Young AT; Ly KN; Wilson C; Lehnert K; Snell RG; Reid SJ; Jacobsen JC
    Dis Model Mech; 2018 Nov; 11(11):. PubMed ID: 30266839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.
    Ng J; Cortès-Saladelafont E; Abela L; Termsarasab P; Mankad K; Sudhakar S; Gorman KM; Heales SJR; Pope S; Biassoni L; Csányi B; Cain J; Rakshi K; Coutts H; Jayawant S; Jefferson R; Hughes D; García-Cazorla À; Grozeva D; Raymond FL; Pérez-Dueñas B; De Goede C; Pearson TS; Meyer E; Kurian MA
    Mov Disord; 2020 Aug; 35(8):1357-1368. PubMed ID: 32472658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.
    Kurian MA; Li Y; Zhen J; Meyer E; Hai N; Christen HJ; Hoffmann GF; Jardine P; von Moers A; Mordekar SR; O'Callaghan F; Wassmer E; Wraige E; Dietrich C; Lewis T; Hyland K; Heales S; Sanger T; Gissen P; Assmann BE; Reith ME; Maher ER
    Lancet Neurol; 2011 Jan; 10(1):54-62. PubMed ID: 21112253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel missense variant in
    Padmakumar M; Jaeken J; Ramaekers V; Lagae L; Greene D; Thys C; Van Geet C; BioResource N; Stirrups K; Downes K; Turro E; Freson K
    JIMD Rep; 2019 May; 47(1):9-16. PubMed ID: 31240161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular monoamine transporter 2 (SLC18A2) regulates monoamine turnover and brain development in zebrafish.
    Baronio D; Chen YC; Decker AR; Enckell L; Fernández-López B; Semenova S; Puttonen HAJ; Cornell RA; Panula P
    Acta Physiol (Oxf); 2022 Jan; 234(1):e13725. PubMed ID: 34403568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
    Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
    J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infantile parkinsonism-dystonia: a dopamine "transportopathy".
    Blackstone C
    J Clin Invest; 2009 Jun; 119(6):1455-8. PubMed ID: 19504720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.
    Glatt CE; Wahner AD; White DJ; Ruiz-Linares A; Ritz B
    Hum Mol Genet; 2006 Jan; 15(2):299-305. PubMed ID: 16339215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic analysis of P387L mutation in SLC18A2 gene in sporadic Parkinson's disease in Chinese Han population.
    Kang J; Tang B; Li K; Liu Z; Yan X; Guo J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 40(8):825-8. PubMed ID: 26333488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.